Neurogene Announces Oversubscribed $200 Million Private Placement
Neurogene has secured an oversubscribed $200 million PIPE financing with participation from major healthcare funds. The company is selling 1,835,000 common stock shares at $50.00 per share and 2,165,042 pre-funded warrants at $49.999 each. The funding, expected to close around November 5, 2024, will extend the company's runway into second half of 2027. The proceeds will support NGN-401's registrational study for Rett syndrome, CMC scale-up, and EXACT™ gene therapy pipeline development. The company will present interim clinical data from the NGN-401 Phase 1/2 trial on November 11, 2024.
Neurogene ha assicurato un finanziamento PIPE da 200 milioni di dollari con una partecipazione da parte di importanti fondi sanitari. La società sta vendendo 1.835.000 azioni ordinarie a 50,00 dollari per azione e 2.165.042 warrants pre-finanziati a 49,999 dollari ciascuno. Il finanziamento, previsto per chiudere intorno al 5 novembre 2024, estenderà la durata dell'azienda fino alla seconda metà del 2027. I proventi supporteranno lo studio registrativo di NGN-401 per la sindrome di Rett, l'espansione della produzione CMC e lo sviluppo della pipeline di terapia genica EXACT™. L'azienda presenterà dati clinici interim dal trial di fase 1/2 di NGN-401 l'11 novembre 2024.
Neurogene ha asegurado un financiamiento PIPE de 200 millones de dólares con la participación de importantes fondos de salud. La empresa está vendiendo 1,835,000 acciones ordinarias a 50.00 dólares por acción y 2,165,042 garantías pre-financiadas a 49.999 dólares cada una. El financiamiento, que se espera cerrar alrededor del 5 de noviembre de 2024, extenderá el horizonte de la empresa hasta la segunda mitad de 2027. Los ingresos apoyarán el estudio registracional de NGN-401 para el síndrome de Rett, la ampliación de CMC y el desarrollo de la terapia génica EXACT™. La compañía presentará datos clínicos intermedios del ensayo de fase 1/2 de NGN-401 el 11 de noviembre de 2024.
Neurogene는 주요 헬스케어 펀드의 참여로 2억 달러 규모의 PIPE 자금을 확보했습니다. 회사는 주당 50.00달러에 1,835,000주 보통주와 각 49.999달러에 2,165,042개의 사전 자금 보증서를 판매하고 있습니다. 이번 자금 조달은 2024년 11월 5일경에 마감될 예정이며, 회사의 운영 기간을 2027년 하반기까지 연장할 것입니다. 수익은 Rett 증후군을 위한 NGN-401의 등록 연구, CMC 확대 및 EXACT™ 유전자 치료 파이프라인 개발을 지원합니다. 회사는 2024년 11월 11일에 NGN-401 1/2상 시험의 중간 임상 데이터를 발표할 예정입니다.
Neurogene a sécurisé un financement PIPE de 200 millions de dollars avec la participation de fonds de santé majeurs. L'entreprise vend 1 835 000 actions ordinaires à 50,00 dollars chacune et 2 165 042 bons de souscription préfinancés à 49,999 dollars chacun. Le financement, qui devrait être conclu autour du 5 novembre 2024, prolongera la durée de l'entreprise jusqu'au second semestre 2027. Les fonds soutiendront l'étude enregistrée de NGN-401 pour le syndrome de Rett, l'augmentation de la production CMC et le développement de la pipeline de thérapie génique EXACT™. L'entreprise présentera des données cliniques intermédiaires de l'essai NGN-401 de phase 1/2 le 11 novembre 2024.
Neurogene hat eine überzeichnete PIPE-Finanzierung in Höhe von 200 Millionen Dollar gesichert, an der bedeutende Gesundheitsfonds teilgenommen haben. Das Unternehmen verkauft 1.835.000 Stammaktien zu je 50,00 Dollar und 2.165.042 vorfinanzierte Warrants zu je 49,999 Dollar. Die Finanzierung, die voraussichtlich um den 5. November 2024 abgeschlossen wird, wird die Laufzeit des Unternehmens bis zur zweiten Hälfte von 2027 verlängern. Die Erlöse werden die registrierungsrelevante Studie zu NGN-401 für das Rett-Syndrom, den CMC-Ausbau und die Entwicklung der EXACT™-Gentherapiepipeline unterstützen. Das Unternehmen wird am 11. November 2024 interimistische klinische Daten aus der NGN-401-Phase 1/2-Studie präsentieren.
- Secured substantial $200 million in PIPE financing
- Extended cash runway into second half of 2027
- Strong investor participation from top-tier healthcare funds
- Premium pricing at $50.00 per share
- Potential dilution from issuance of 4 million new shares and warrants
- Securities not registered under Securities Act, limiting transferability
Insights
This
The extended cash runway into 2027 provides important operational flexibility for advancing NGN-401's Rett syndrome program through registrational studies. With approximately 21 million shares outstanding post-transaction, the deal structure balances dilution with capital needs. The pre-funded warrants at
The substantial funding secured will accelerate the development of NGN-401 for Rett syndrome, a severe neurological disorder with significant unmet medical needs. The upcoming data readout from both dose cohorts represents a important clinical milestone that could validate Neurogene's gene therapy approach. The company's ability to attract top-tier healthcare investors suggests confidence in the preliminary efficacy signals.
The extended runway ensures sufficient resources for CMC scale-up and manufacturing optimization, critical aspects for gene therapy commercialization. The funding also supports expansion of their EXACT™ gene therapy platform, potentially enabling development of treatments for additional rare neurological conditions.
Financing included participation from top-tier healthcare funds
Proceeds expected to fund Company into the second half of 2027
Company to host webcast to review interim clinical data from Phase 1/2 trial of
Pursuant to the terms of the securities purchase agreement, Neurogene is selling an aggregate of (i) 1,835,000 shares of its common stock (“Common Stock”) at a purchase price of
Neurogene expects the net proceeds from the PIPE financing along with its existing cash and cash equivalents will provide runway into the second half of 2027. Neurogene anticipates the funding will allow for the completion of enrollment of a future registrational study for
Neurogene will host a webcast to review the safety data from the low- and high-dose cohorts and interim efficacy data from the low-dose cohort of the
TD Cowen, Leerink Partners, Stifel and William Blair are acting as joint placement agents for the private placement.
The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Neurogene
The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. Neurogene’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: the intended use of proceeds from the PIPE financing, Neurogene’s cash sufficiency and runway, the expected timing of closing of the PIPE financing and the completion of the PIPE financing, Neurogene’s business plans; and its expected cash resources and liquidity. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “on track,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene’s control. Such risks, uncertainties and assumptions include, among other things: market conditions and the satisfaction of the customary closing conditions, and other risks and uncertainties identified under the heading "Risk Factors" included in Neurogene’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 18, 2024, or its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and other filings that Neurogene has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104841591/en/
Company Contact:
Cara Mayfield
Vice President, Corporate Affairs
cara.mayfield@neurogene.com
Investor Contact:
Melissa Forst
Argot Partners
Neurogene@argotpartners.com
Source: Neurogene Inc.
FAQ
How much did Neurogene (NGNE) raise in the PIPE financing?
When will Neurogene's (NGNE) PIPE financing close?
How long will the PIPE financing extend Neurogene's (NGNE) cash runway?